<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2928">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04389320</url>
  </required_header>
  <id_info>
    <org_study_id>covid 19 in RA</org_study_id>
    <nct_id>NCT04389320</nct_id>
  </id_info>
  <brief_title>Antimalarial and Covid 19 in Rheumatoid Arthritis</brief_title>
  <official_title>Antimalarial and Covid 19 in Rheumatoid Arthritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assiut University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assiut University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The antimalarial agent hydroxychloroquine(HCQ) have been used widely used for the treatment
      of rheumatoid arthritis and systemic lupus erythematosus. These compounds lead to improvement
      of clinical and laboratory parameters, but their slow onset of action differ them from
      glucocorticoids and nonsteroidal antiinflammatory agents.

      Among rheumatic diseases, the primary role of HCQ is in the management of articular and skin
      manifestations of systemic lupus erythematosus (SLE) and the treatment of mild to moderately
      active rheumatoid arthritis (RA).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The antimalarial agent hydroxychloroquine(HCQ) have been used widely used for the treatment
      of rheumatoid arthritis and systemic lupus erythematosus.(1) . These compounds lead to
      improvement of clinical and laboratory parameters, but their slow onset of action differ them
      from glucocorticoids and nonsteroidal antiinflammatory agents.

      Among rheumatic diseases, the primary role of HCQ is in the management of articular and skin
      manifestations of systemic lupus erythematosus (SLE) and the treatment of mild to moderately
      active rheumatoid arthritis (RA).

      It is difficult to carefully evaluate the onslaught of information that has emerged regarding
      potential COVID-19 therapies within a few months' time in early 2020. A brief but detailed
      approach regarding how to evaluate resulting evidence of a study has been presented by F.
      Perry Wilson, MD, MSCE. By using the example of a case series of patients given
      hydroxychloroquine plus azithromycin, he provides clinicians with a quick review of critical
      analyses.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 15, 2020</start_date>
  <completion_date type="Actual">May 1, 2020</completion_date>
  <primary_completion_date type="Actual">May 1, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>immunoglobulin mesurement</measure>
    <time_frame>1 month</time_frame>
    <description>serum level</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">60</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>Rheumatoid patients receiving hydroxychloroquine</arm_group_label>
    <description>immunoglobulin analyses of covid 19 virus in patients already on hydroxychloroquine and relation to clinical presentation and genetics</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hydroxychloroquine</intervention_name>
    <description>assess its role in the coarse of covid 19 virus infection</description>
    <arm_group_label>Rheumatoid patients receiving hydroxychloroquine</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        rheumatoid arthritis patients
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  rheumatoid arthritis recieving hydroxychloroquine chest infection

        Exclusion Criteria:

          -  patients not used hydroxychloroquine
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Manal Hassanien</name>
      <address>
        <city>Assiut</city>
        <state>Yes</state>
        <zip>7111</zip>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>May 11, 2020</study_first_submitted>
  <study_first_submitted_qc>May 13, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 15, 2020</study_first_posted>
  <last_update_submitted>May 13, 2020</last_update_submitted>
  <last_update_submitted_qc>May 13, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 15, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Assiut University</investigator_affiliation>
    <investigator_full_name>Manal Hassanien</investigator_full_name>
    <investigator_title>Assistant professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hydroxychloroquine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

